1. Home
  2. EVT vs LQDA Comparison

EVT vs LQDA Comparison

Compare EVT & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EVT
  • LQDA
  • Stock Information
  • Founded
  • EVT 2003
  • LQDA 2004
  • Country
  • EVT United States
  • LQDA United States
  • Employees
  • EVT N/A
  • LQDA 170
  • Industry
  • EVT Finance Companies
  • LQDA Biotechnology: Pharmaceutical Preparations
  • Sector
  • EVT Finance
  • LQDA Health Care
  • Exchange
  • EVT Nasdaq
  • LQDA Nasdaq
  • Market Cap
  • EVT 1.7B
  • LQDA 1.3B
  • IPO Year
  • EVT N/A
  • LQDA 2018
  • Fundamental
  • Price
  • EVT $23.21
  • LQDA $14.92
  • Analyst Decision
  • EVT
  • LQDA Strong Buy
  • Analyst Count
  • EVT 0
  • LQDA 8
  • Target Price
  • EVT N/A
  • LQDA $27.13
  • AVG Volume (30 Days)
  • EVT 140.9K
  • LQDA 2.1M
  • Earning Date
  • EVT 01-01-0001
  • LQDA 05-08-2025
  • Dividend Yield
  • EVT 8.50%
  • LQDA N/A
  • EPS Growth
  • EVT N/A
  • LQDA N/A
  • EPS
  • EVT 6.63
  • LQDA N/A
  • Revenue
  • EVT $69,404,302.00
  • LQDA $14,144,000.00
  • Revenue This Year
  • EVT N/A
  • LQDA $224.65
  • Revenue Next Year
  • EVT N/A
  • LQDA $250.54
  • P/E Ratio
  • EVT $3.51
  • LQDA N/A
  • Revenue Growth
  • EVT N/A
  • LQDA N/A
  • 52 Week Low
  • EVT $19.20
  • LQDA $8.26
  • 52 Week High
  • EVT $25.83
  • LQDA $19.41
  • Technical
  • Relative Strength Index (RSI)
  • EVT 55.70
  • LQDA 45.94
  • Support Level
  • EVT $22.89
  • LQDA $13.94
  • Resistance Level
  • EVT $23.29
  • LQDA $17.88
  • Average True Range (ATR)
  • EVT 0.35
  • LQDA 1.40
  • MACD
  • EVT -0.03
  • LQDA -0.33
  • Stochastic Oscillator
  • EVT 54.12
  • LQDA 17.92

About EVT Eaton Vance Tax Advantaged Dividend Income Fund of Beneficial Interest

EATON VANCE TAX ADVANTAGED DIVIDEND INCOME FUND is a diversified, closed-end management investment company. Its objective is to provide a high level of after-tax total return consisting mainly of tax-advantaged dividend income and capital appreciation. The fund pursues its objective by investing in dividend-paying common and preferred stocks. Its portfolio of investments consists of electric utilities, energy equipment and services, food products, health care providers and services, internet software and services, and other areas.

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

Share on Social Networks: